

Supplementary Table 2. Clinical characteristics according to the use of DPP-4i in Korean COVID-19 patients with diabetes based on the NHID-COVID database from the National Health Insurance Service of Korea

Characteristic	No DPP-4i user (n=529)	DPP-4i user (n=175)	P value
Age group, yr			0.117
<40	15 (2.9)	1 (0.6)	
40 to <50	45 (8.5)	10 (5.7)	
50 to <60	137 (25.9)	43 (24.6)	
60 to <70	159 (30.1)	71 (40.6)	
70 to <80	111 (21.0)	35 (20.0)	
≥80	62 (11.7)	15 (8.6)	
Male sex	201 (38.0)	83 (47.4)	0.034
Height, cm	160.4±8.7	160.0±9.1	0.801
Weight, kg	63.1±11.8	65.7±10.8	0.009
BMI, kg/m ²	24.4±3.5	25.4±3.1	0.001
Waist circumference, cm	82.9±9.2	85.8±8.7	<0.001
SBP, mm Hg	125.0±15.2	128.0±16.7	0.029
DBP, mm Hg	76.0±9.9	77.1±10.6	0.205
Fasting glucose, mg/dL	111.7±39.2	141.3±57.3	<0.001
Total cholesterol, mg/dL	193.3±41.1	177.5±38.0	<0.001
Smoking	47 (8.9)	12 (6.9)	0.298
Drinking	40 (7.6)	17 (9.7)	0.542
Regular exercise	126 (23.8)	47 (26.9)	0.479
Hypertension	271 (51.2)	117(66.9)	<0.001
Dyslipidemia	466 (88.1)	165 (94.3)	0.029
Cardiovascular disease	376 (71.1)	138 (78.9)	0.056
Cerebrovascular disease	59 (11.2)	20 (11.4)	1.000
Chronic kidney disease	9 (1.7)	7 (4.0)	0.140
Asthma	138 (26.1)	50 (28.6)	0.585
COPD	38 (7.2)	6 (3.4)	0.110
Cancer	12 (2.3)	5 (2.9)	0.876
Medication			
Metformin	79 (14.9)	143 (81.7)	<0.001
Sulfonylurea	31 (5.9)	55 (31.4)	<0.001
Meglitinide	0	0	NA
TZD	7 (1.3)	14 (8.0)	<0.001
DPP-4i	0	175 (100.0)	<0.001
SGLT2i	16 (3.0)	0	0.042
AGI	2 (0.4)	0	1.000
Insulin	0	0	NA
RAS blockade	127 (24.0)	85 (48.6)	<0.001
ACEi	6 (1.1)	4 (2.3)	0.455
ARB	121 (22.9)	81 (46.3)	<0.001
Beta blocker	37 (7.0)	17 (9.7)	0.313
Diuretics	45 (8.5)	31 (17.7)	0.001
CCB	98 (18.5)	50 (28.6)	0.007
Statin	152 (28.7)	106 (60.6)	<0.001
Fibrate	6 (1.1)	9 (5.1)	0.004

Values are presented as number (%) or mean ± standard deviation.

DPP-4i, dipeptidyl peptidase-4 inhibitor; COVID-19, coronavirus disease 2019; NHID, National Health Information Database; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; COPD, chronic obstructive pulmonary disease; NA, not applicable; TZD, thiazolidinedione; SGLT2i, sodium glucose cotransporter 2 inhibitor; AGI, alpha glucosidase inhibitor; RAS, renin-angiotensin system; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium-channel blocker.